|
1.
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2.
|
Gustin DM and Brenner DE: Chemoprevention
of colon cancer: current status and future prospects. Cancer
Metastasis Rev. 21:323–348. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Gorlick R and Bertino JR: Drug resistance
in colon cancer. Semin Oncol. 26:606–611. 1999.
|
|
4.
|
Longley DB, Allen WL and Johnston PG: Drug
resistance, predictive markers and pharmacogenomics in colorectal
cancer. Biochim Biophys Acta. 1766:184–196. 2006.PubMed/NCBI
|
|
5.
|
Aggarwal BB, Kunnumakkara AB, Harikumar
KB, Gupta SR, Tharakan ST, Koca C, Dey S and Sung B: Signal
transducer and activator of transcription-3, inflammation, and
cancer: how intimate is the relationship? Ann NY Acad Sci.
1171:59–76. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Zhong Z, Wen Z and Darnell J: Stat3: a
STAT family member activated by tyrosine phosphorylation in
response to epidermal growth factor and interleukin-6. Science.
264:95–98. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Bromberg J and Wang TC: Inflammation and
cancer: IL-6 and STAT3 complete the link. Cancer Cell. 15:79–80.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Kusaba T, Nakayama T, Yamazumi K, Yakata
Y, Yoshizaki A, Inoue K, Nagayasu T and Sekine I: Activation of
STAT3 is a marker of poor prognosis in human colorectal cancer.
Oncol Rep. 15:1445–1451. 2006.PubMed/NCBI
|
|
9.
|
Lin Q, Lai R, Chirieac LR, Li C, Thomazy
VA, Grammatikakis I, Rassidakis GZ, Zhang W, Fujio Y, Kunisada K,
Hamilton SR and Amin HM: Constitutive activation of JAK3/STAT3 in
colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3
signaling induces apoptosis and cell cycle arrest of colon
carcinoma cells. Am J Pathol. 167:969–980. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Xiong H, Zhang Z, Tian X, Sun D, Liang Q,
Zhang Y, Lu R, Chen Y and Fang J: Inhibition of JAK1, 2/STAT3
signaling induces apoptosis, cell cycle arrest, and reduces tumor
cell invasion in colorectal cancer cells. Neoplasia. 10:287–297.
2008.PubMed/NCBI
|
|
11.
|
Sebolt-Leopold JS: Development of
anticancer drugs targeting the MAP kinase pathway. Oncogene.
19:6594–6599. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Seger R and Krebs EG: The MAPK signaling
cascade. FASEB J. 9:726–735. 1995.PubMed/NCBI
|
|
13.
|
Taupin D and Podolski DK:
Mitogen-activated protein kinase activation regulates intestinal
epithelial differentiation. Gastroenterology. 116:1072–1080. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Wang X, Wang Q, Hu W and Evers BM:
Regulation of phorbol estermediated TRAF1 induction in human colon
cancer cells through a PKC/RAF/ERK/NF-kappaB-dependent pathway.
Oncogene. 23:1885–1895. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Roberts PJ and Der CJ: Targeting the
Raf-MEK-ERK mitogen-activated protein kinase cascade for the
treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Schwartsmann G, Di Leone LP, Dal Pizzol F
and Roesler R: MAPK pathway activation in colorectal cancer: a
therapeutic opportunity for GRP receptor antagonists. Lancet Oncol.
6:444–445. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Fang JY and Richardson BC: The MAPK
signalling pathways and colorectal cancer. Lancet Oncol. 6:322–327.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Ma XH and Wang ZW: Anticancer drug
discovery in the future: an evolutionary perspective. Drug Discov
Today. 14:1136–1142. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Gordaliza M: Natural products as leads to
anticancer drugs. Clin Transl Oncol. 9:767–776. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Lin JM, Chen YQ, Wei LH, Chen XZ, Xu W,
Hong ZF, Sferra TJ and Peng J: Hedyotis Diffusa Willd
extract induces apoptosis via activation of the
mitochondrion-dependent pathway in human colon carcinoma cells. Int
J Oncol. 37:1331–1338. 2010.
|
|
21.
|
Cai QY, Lin JM, Wei LH, Zhang L, Wang LL,
Zhan YZ, Zeng JW, Xu W, Shen AL, Hong ZF and Peng J: Hedyotis
diffusa Willd inhibits colorectal cancer growth in vivo via
inhibition of STAT3 signaling pathway. Int J Mol Sci. 13:6117–6128.
2012. View Article : Google Scholar
|
|
22.
|
Wei LH, Chen YQ, Lin JM, Zhao JY, Chen XZ,
Xu W, Liu XX, Sferra TJ and Peng J: Scutellaria Barbata D.
Don induces apoptosis of human colon carcinoma cell via activation
of the mitochondrion-dependent pathway. J Med Plants Res.
5:1962–1970. 2011.
|
|
23.
|
Zheng LP, Chen YQ, Lin W, Zhuang QC, Chen
XZ, Xu W, Liu XX, Peng J and Sferra TJ: Spica Prunellae
extract promotes mitochondrion-dependent apoptosis in a human colon
carcinoma cell line. Afr J Pharm Pharmacol. 5:327–335. 2011.
View Article : Google Scholar
|
|
24.
|
Ikeda Y, Murakami A and Ohigashi H:
Ursolic acid: an anti- and pro-inflammatory triterpenoid. Mol Nutr
Food Res. 52:26–42. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Xavier CP, Lima CF, Preto A, Seruca R,
Fernandes-Ferreira M and Pereira-Wilson C: Luteolin, quercetin and
ursolic acid are potent inhibitors of proliferation and inducers of
apoptosis in both KRAS and BRAF mutated human colorectal cancer
cells. Cancer Lett. 281:162–170. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Andersson D, Liu JJ, Nilsson A and Duan
RD: Ursolic acid inhibits proliferation and stimulates apoptosis in
HT29 cells following activation of alkaline sphingomyelinase.
Anticancer Res. 23:3317–3322. 2003.PubMed/NCBI
|
|
27.
|
Adams J and Cory S: The Bcl-2 apoptotic
switch in cancer development and therapy. Oncogene. 26:1324–1337.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Youle RJ and Strasser A: The BCL-2 protein
family: opposing activities that mediate cell death. Nat Rev Mol
Cell Biol. 9:47–59. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Nurse P: Ordering S phase and M phase in
the cell cycle. Cell. 79:547–550. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Morgan DO: Principles of CDK regulation.
Nature. 374:131–134. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Zafonte BT, Hulit J, Amanatullah DF,
Albanese C, Wang C, Rosen E, Reutens A, Sparano JA, Lisanti MP and
Pestell RG: Cell-cycle dysregulation in breast cancer: breast
cancer therapies targeting the cell cycle. Front Biosci.
5:D938–D961. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Kouraklis G, Theocharis S, Vamvakas P,
Vagianos C, Glinavou A, Giaginis C and Sioka C: Cyclin D1 and Rb
protein expression and their correlation with prognosis in patients
with colon cancer. World J Surg Oncol. 4:52006. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Domagala W, Welcker M, Chosia M,
Karbowniczek M, Harezga B, Bartkova J, Bartek J and Osborn M:
p21/WAF1/Cip1 expression in invasive ductal breast carcinoma:
Relationship to p53, proliferation rate, and survival at 5 years.
Virchows Arch. 439:132–140. 2001.PubMed/NCBI
|
